Health Canada has requested all manufacturers of botulinum toxin products to revise their product labels in a bid to help prevent medication errors with their use.
According to Health Canada, the new labeling should reflect in such a way that each product has its own individual potency and is not interchangeable with other botulinum products, as such.
The amendments in labeling are due to a risk evaluation of the active ingredients (Clostridium botulinum toxin type A and type B) within the products.
Available currently on the Canadian market, the products that will be impacted by labeling changes include Botox / Botox Cosmetic, Xeomin / Xeomin Cosmetic, Dysport and Myobloc.
Source:
http://otcproducts.packaging-business-review.com/news/health-canada-calls-for-toxin-products-labeling-revision-220113
